WiseTech Lifts Dividend, Margin Guidance After 1st Half Profit Rises 5%
By Stuart Condie
SYDNEY--WiseTech Global raised its dividend and lifted the top end of its full-year margin guidance range after the logistics software provider's first-half profit rose by 5%.
The ASX-listed company on Wednesday reported an underlying net profit for the six months through December of 128.4 million Australian dollars (US$84.0 million), compared with A$121.8 million a year earlier. Revenue rose by 32% to A$500.4 million.
Including one-off items, statutory profit rose by 8% to A$118.2 million. Earnings before interest, tax, depreciation and amortization rose by 23% to A$229.9 million, with an Ebitda margin of 46% beating both market and analysts' expectations.
The average analyst forecast was for A$205 million in Ebitda from revenue of A$496 million, according to data compiled by FactSet. That had implied an Ebitda margin forecast of 41%.
WiseTech maintained its full-year revenue and Ebitda guidance, but lifted the top end of its Ebitda margin guidance on the strong first-half performance. It now sees an annual Ebitda margin of 44-46%, compared with the 44-45% it previously expected.
The board declared an interim dividend of 7.7 Australian cents, compared with 6.6 Australian cents a year earlier.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
February 20, 2024 17:04 ET (22:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks